## NATIONAL CANCER STRATEGY 2017-2026

## Key Performance Indicators: December 2020

	Objective/Action	Performance Indicator	Target	Target Date	End 2020 Position
1	Reduce the proportion of adults in the population who smoke	Percentage of adults (aged 15+) in population smoking daily	5%	2025 (interim 17% by 2018)	2015: 23% 2019: 17%
	who shoke			17% by 2018)	(2019 Annual Healthy Ireland Survey)
2	Introduce cancer awareness campaigns for specific	Percentage of lung cancers diagnosed at	15% relative	One year after	The NCCP collaborated with the voluntary sector to conduct lung cancer public
	diseases (e.g. Lung Cancer)	Stage I and II one year following	increase	awareness	awareness campaigns in September and November 2020.
2	Expand electronic referrals for all GD cancer	awareness campaign Percentage of GP referrals received	95%	campaign End 2022	Jan - Dec 2020
3	Expand electronic referrals for all GP cancer referrals	electronically	95%	(interim 75% by	>95% at Symptomatic Breast Disease Clinics
		cicculomouny		end 2019)	>95% at Prostate Rapid Access Clinics
					47% at Lung Rapid Access Clinics <sup>1</sup>
					(NCCP)
4	Increase proportion of cancers diagnosed early	Percentage of colorectal, breast, and lung	10% relative	2020	Baseline Figure - 2013: 2014: 2015:
		cancers diagnosed at Stage I and II	increase on		Colorectal: 39% Colorectal: 38.4% Colorectal: 39.7%
			2013 figures		Breast: 79%   Breast: 77.3%   Breast: 79.7%     Lung: 27.5%   Lung: 25.8%   Lung: 28.7%
					(NCRI)
5	Ensure Rapid Access Clinic and Symptomatic Breast	Percentage of new patients attending RAC	95%	2017	Jan-Dec 2020 (Patient Numbers):
	Disease Clinic targets are met	or SBD clinic within timeframe			Breast: 70.4% (20,175)
					Lung: 86.7% (3,319)
					Prostate: 51.8% (3,036)
~			0.00/	2020	(NCCP)
	Ensure GPs have direct access to diagnostics for patients meeting referral criteria	Percentage of patients accessing imaging/diagnostics/endoscopy within	90%	2020	The improvements made for GP access to diagnostics generally, in the context of Covid-19, have impacted positively on cancer patients. Direct access to MRI, CT, X
	patients meeting referral criteria	agreed timelines			Ray and DEXA scans is available to GPs for GMS patients in Community Healthcare
					Organisations (CHOs).
					(Percentages not available)
7	Reduce the proportion of cancers detected in	Percentage of cancers diagnosed in	50% relative	2026	2013: 13.5%
	Emergency Departments	Emergency Departments	decrease over		2015-2017: 13.9% <sup>2</sup>
			2013 figure		(NCRI)
8	Maintain target uptake rate for BreastCheck	Percentage uptake rate for BreastCheck	70%	2017-2026	Jan-Sept 2020: 67%
_		screening population			(NSS)
9	Achieve target coverage rate for CervicalCheck	Percentage five year rolling coverage of	80%	2017-2026	Jan-Sept 2020 76.8%
		CervicalCheck in screening population			(NSS)
10	Achieve target uptake rate for BowelScreen	Percentage uptake rate for BowelScreen	60%	2020 (interim	Jan-Sept 2020: 44.7%
		screening population		measure of 45%	(NSS)
				by end 2018)	
11	Complete centralisation of cancer surgical services		95%	Various target	2020: 87% <sup>3</sup>
17	Ensure that patients have their case discussed at an	approved centres	95%	dates to 2020 End 2020	(NCCP) Breast, lung, prostate, and rectal cancers combined:
12	MDT meeting	invasive cancers formally discussed at	93%	Ella 2020	Jan-Sept 2020: 94%
	in brineeting	MDT meetings			(NCCP)
13	Ensure that patients on active treatment receive	Percentage of patients on active cancer	Less than 20%	2018	The National Cancer Information System, which is in operation in four sites, will
	appropriate admission in emergency situations	treatment admitted to hospital for cancer			facilitate collection of the relevant data when it has been rolled out nationally.
		treatment that are admitted through			Part of the work of 26 Acute Oncology nurses, recruited in 2020, is to faciliatate
	For an analysis of the second s	Emergency Departments.	80%	2020	appropriate admission in emergency situations.
14	Ensure patients with cancer are admitted to cancer units	Percentage of patients requiring active treatment for their cancer admitted to	80%	2020	The NCCP is working to develop this pathway and to ascertain how best to capture the data.
		dedicated cancer units in hospitals			
15	Reduce waiting times for surgery	Percentage of patients seen within NCCP	90%	2017	Jan-Jun 2020
		target surgery timeframes for defined			Breast: 77%
10		cancers	90%	2017	Lung: 55% 2020: 82.2%
10	Achieve the radiotherapy treatment target	Percentage of patients commencing treatment within 15 working days of being		2017	(NCCP)
		deemed ready to treat			
17	Offer patients with cancer a Treatment Summary	Percentage of patients receiving a	95%	2020; interim	The NCCP's Survivorship Working Group is progressing the development of a
	and Care Plan	Treatment Summary and Care Plan		target 50% by	Model Patient Treatment Summary and Care Plan. A Colorectal Patient Passport is
				2018	in pilot phase in a number of hospitals (Strategy Recommendation 40).
18	Avoid chemotherapy in patients with advanced	Percentage of patients with metastatic	Less than 25%	2019	The National Cancer Information System, which is in operation in four sites, will facilitate collection of the relevant data when it has been rolled out nationally
	cancer who are unlikely to benefit as they are in the terminal phase of their disease	cancer given chemotherapy in last month of life			facilitate collection of the relevant data when it has been rolled out nationally.
19	Increase proportion of patients receiving specialist	Percentage of patients with cancer with	90%	2019	The National Cancer Information System, which is in operation in four sites, will
	palliative care	Stage IV disease receiving specialist			facilitate collection of the relevant data when it has been rolled out nationally.
		palliative care			
_			6%	2020	2017: 3% <sup>4</sup>
20	Increase patient participation in clinical trials	Percentage of patients on cancer			(Cancer Trials Ireland)
		therapeutic clinical trials			· · · · · · · · · · · · · · · · · · ·
	Improve Ireland's cancer ranking among EU	therapeutic clinical trials Ireland to be in top quartile for five year	Top Quartile	2026	5-Year Survival 2010-2014:
		therapeutic clinical trials	for overall	2026	5-Year Survival 2010-2014:     Oesophagus: 4 of 22   Pancreas: 8 of 23   Liver: 9 of 23
	Improve Ireland's cancer ranking among EU	therapeutic clinical trials Ireland to be in top quartile for five year	•	2026	5-Year Survival 2010-2014:Oesophagus: 4 of 22Pancreas: 8 of 23Liver: 9 of 23Brain: 4 of 23Melanoma Skin: 8 of 24Colon: 13 of 24
	Improve Ireland's cancer ranking among EU	therapeutic clinical trials Ireland to be in top quartile for five year	for overall	2026	5-Year Survival 2010-2014:Oesophagus: 4 of 22Pancreas: 8 of 23Liver: 9 of 23Brain: 4 of 23Melanoma Skin: 8 of 24Colon: 13 of 24
	Improve Ireland's cancer ranking among EU	therapeutic clinical trials Ireland to be in top quartile for five year	for overall	2026	5-Year Survival 2010-2014:Oesophagus: 4 of 22Pancreas: 8 of 23Liver: 9 of 23Brain: 4 of 23Melanoma Skin: 8 of 24Colon: 13 of 24Lymphoma: 4 of 21Stomach: 9 of 24Cervix: 16 of 24
	Improve Ireland's cancer ranking among EU	therapeutic clinical trials Ireland to be in top quartile for five year	for overall	2026	5-Year Survival 2010-2014:     Oesophagus: 4 of 22   Pancreas: 8 of 23   Liver: 9 of 23     Brain: 4 of 23   Melanoma Skin: 8 of 24   Colon: 13 of 24     Lymphoma: 4 of 21   Stomach: 9 of 24   Cervix: 16 of 24     Lung: 6 of 24   Rectum: 9 of 24   Breast: 16 of 24
21	Improve Ireland's cancer ranking among EU member states	therapeutic clinical trials Ireland to be in top quartile for five year survival among EU member states	for overall survival		5-Year Survival 2010-2014:Oesophagus: 4 of 22Pancreas: 8 of 23Liver: 9 of 23Brain: 4 of 23Melanoma Skin: 8 of 24Colon: 13 of 24Lymphoma: 4 of 21Stomach: 9 of 24Cervix: 16 of 24Lung: 6 of 24Rectum: 9 of 24Breast: 16 of 24Prostate: 6 of 24Liver: 9 of 23Ovary: 23 of 24(CONCORD - International Cancer Survival Comparisons)
21	Improve Ireland's cancer ranking among EU member states Reduce inequalities in age standardised cancer	therapeutic clinical trials Ireland to be in top quartile for five year survival among EU member states Comparison between bottom 20%	for overall survival Difference no	2026	5-Year Survival 2010-2014:Oesophagus: 4 of 22Pancreas: 8 of 23Liver: 9 of 23Brain: 4 of 23Melanoma Skin: 8 of 24Colon: 13 of 24Lymphoma: 4 of 21Stomach: 9 of 24Cervix: 16 of 24Lung: 6 of 24Rectum: 9 of 24Breast: 16 of 24Prostate: 6 of 24Liver: 9 of 23Ovary: 23 of 24(CONCORD - International Cancer Survival Comparisons)Incidence is 3.8% higher in most-deprived 20% compared to least deprived 20%
21	Improve Ireland's cancer ranking among EU member states	therapeutic clinical trials Ireland to be in top quartile for five year survival among EU member states Comparison between bottom 20%	for overall survival Difference no greater than		5-Year Survival 2010-2014:   Oesophagus: 4 of 22 Pancreas: 8 of 23 Liver: 9 of 23   Brain: 4 of 23 Melanoma Skin: 8 of 24 Colon: 13 of 24   Lymphoma: 4 of 21 Stomach: 9 of 24 Cervix: 16 of 24   Lung: 6 of 24 Rectum: 9 of 24 Breast: 16 of 24   Prostate: 6 of 24 Liver: 9 of 23 Ovary: 23 of 24   (CONCORD - International Cancer Survival Comparisons) Incidence is 3.8% higher in most-deprived 20% compared to least deprived 20%
21	Improve Ireland's cancer ranking among EU member states Reduce inequalities in age standardised cancer incidence for all malignant neoplasms (excl. NMSC)	therapeutic clinical trials Ireland to be in top quartile for five year survival among EU member states Comparison between bottom 20% deprivation vs. top 20%	for overall survival Difference no greater than 3%	2026	5-Year Survival 2010-2014:   Oesophagus: 4 of 22 Pancreas: 8 of 23 Liver: 9 of 23   Brain: 4 of 23 Melanoma Skin: 8 of 24 Colon: 13 of 24   Lymphoma: 4 of 21 Stomach: 9 of 24 Cervix: 16 of 24   Lung: 6 of 24 Rectum: 9 of 24 Breast: 16 of 24   Prostate: 6 of 24 Liver: 9 of 23 Ovary: 23 of 24   (CONCORD - International Cancer Survival Comparisons)   Incidence is 3.8% higher in most-deprived 20% compared to least deprived 20%   (NCRI)
21 22 22	Improve Ireland's cancer ranking among EU member states Reduce inequalities in age standardised cancer	therapeutic clinical trials Ireland to be in top quartile for five year survival among EU member states Comparison between bottom 20%	for overall survival Difference no greater than	2026	5-Year Survival 2010-2014:   Oesophagus: 4 of 22 Pancreas: 8 of 23 Liver: 9 of 23   Brain: 4 of 23 Melanoma Skin: 8 of 24 Colon: 13 of 24   Lymphoma: 4 of 21 Stomach: 9 of 24 Cervix: 16 of 24   Lung: 6 of 24 Rectum: 9 of 24 Breast: 16 of 24   Prostate: 6 of 24 Liver: 9 of 23 Ovary: 23 of 24   (CONCORD - International Cancer Survival Comparisons) Incidence is 3.8% higher in most-deprived 20% compared to least deprived 20% (2008-2012) <sup>5</sup>

<sup>1</sup>Many patients with suspected lung cancer are referred to the Lung Rapid Access Clinics through Emergency Departments, rather than through GPs.

<sup>2</sup> Cumulative over three years 2015-2017.

<sup>3</sup> In light of the impact of the Covid-19 pandemic on hospital theatres, ICU and HDU capacity, much public time-sensitive cancer surgery was undertaken in private hospitals in 2020.

<sup>4</sup> Issues pertaining to the establishment of the total numbers (and the %) of patients on cancer therapeutic clinical trials are being examined.

<sup>5</sup> Figures for 2013-2018 being compiled in NCRI.